Diadema Partners LP Makes New Investment in Evolus, Inc. (NASDAQ:EOLS)

Diadema Partners LP acquired a new position in Evolus, Inc. (NASDAQ:EOLS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 97,423 shares of the company's stock, valued at approximately $1,076,000. Diadema Partners LP owned about 0.15% of Evolus at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in EOLS. Stifel Financial Corp grew its position in Evolus by 37.3% in the fourth quarter. Stifel Financial Corp now owns 197,697 shares of the company's stock worth $2,183,000 after buying an additional 53,673 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Evolus by 513.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 21,496 shares of the company's stock worth $237,000 after acquiring an additional 17,993 shares during the last quarter. Tradition Wealth Management LLC raised its position in shares of Evolus by 18.2% during the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock worth $144,000 after purchasing an additional 2,000 shares during the period. MetLife Investment Management LLC lifted its holdings in shares of Evolus by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 34,272 shares of the company's stock valued at $378,000 after purchasing an additional 2,044 shares during the last quarter. Finally, Altium Capital Management LLC boosted its position in shares of Evolus by 93.0% in the 4th quarter. Altium Capital Management LLC now owns 685,000 shares of the company's stock valued at $7,562,000 after purchasing an additional 330,000 shares during the period. 90.69% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Evolus news, insider Rui Avelar sold 27,904 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $370,007.04. Following the transaction, the insider now directly owns 362,467 shares of the company's stock, valued at $4,806,312.42. This represents a 7.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Sandra Beaver sold 8,996 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $119,286.96. Following the transaction, the chief financial officer now owns 173,583 shares in the company, valued at approximately $2,301,710.58. This trade represents a 4.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 60,575 shares of company stock worth $794,369. Insiders own 6.10% of the company's stock.

Evolus Stock Up 0.9 %

Shares of NASDAQ:EOLS traded up $0.10 during midday trading on Friday, hitting $11.65. 800,262 shares of the stock were exchanged, compared to its average volume of 667,493. The business's fifty day simple moving average is $12.25 and its two-hundred day simple moving average is $12.92. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus, Inc. has a 52-week low of $8.67 and a 52-week high of $17.82. The company has a market capitalization of $740.79 million, a PE ratio of -12.80 and a beta of 0.97.

Analyst Upgrades and Downgrades

A number of analysts have commented on EOLS shares. BTIG Research initiated coverage on shares of Evolus in a research note on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective for the company. Barclays upped their price target on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 target price on shares of Evolus in a research report on Wednesday, April 9th. Finally, HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of Evolus in a report on Thursday, April 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Evolus currently has an average rating of "Buy" and a consensus target price of $23.75.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.